Interferon beta-1a: Clinical Trials

34 trials of Interferon beta-1a, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 completed, 5 unknown, 3 withdrawn, 2 terminated. 34 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 234Completed 23, Unknown 5, Withdrawn 3, Terminated 2, Recruiting 1
Phase 32Completed 2
Phase 11Withdrawn 1

Follow Interferon beta-1a: new trials by email Literature Review of Interferon beta-1a trials Research Report on Interferon beta-1a

Trials (filtered) newest first · largest first

All 34 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2WithdrawnFred Hutchinson Cancer Center2025-04-012024-07-12
Early Interferon-beta Treatment for West-Nile Virus Infection
Rebif 44 MCG Per 0.5 ML Prefilled Syringe, Saline - West Nile Virus, West Nile Fever Encephalitis
Phase 2UnknownTel-Aviv Sourasky Medical Center1002024-07-142024-07-23
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
Nivolumab, Cisplatin, 5-Fluorouracil - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Phase 2RecruitingGerman Society for Pediatric Oncology and Hematology GPOH gGmbH572023-01-102024-05-16
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients
MetFORMIN 1000 Mg Oral Tablet, Interferon beta-1a - Multiple Sclerosis
Phase 2UnknownGerman University in Cairo802022-02-012023-03-20
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis
Phase 2WithdrawnBiogen2021-06-302023-06-01
the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19
High dose Interferon-beta 1a, Lopinavir/Ritonavir, Low dose Interferon-beta 1a - Covid19
Phase 2UnknownShahid Beheshti University of Medical Sciences1002020-08-202020-08-20
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
Hydroxychloroquine, Lopinavir / Ritonavir, Interferon Beta-1A - COVID-19
Phase 2CompletedShahid Beheshti University of Medical Sciences602020-04-092020-05-05
A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza
Interferon Beta-1A, Placebo - Chronic Obstructive Pulmonary Disease (COPD)
Phase 2CompletedSynairgen Research Ltd.1222018-01-292023-01-04
Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis
BCD-054 180 mcg, Avonex®, BCD-054 240 mcg - Multiple Sclerosis, Relapsing-Remitting
Phase 2 / Phase 3CompletedBiocad3992017-08-102021-09-08
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA
Interferon Beta-1A, Placebo - Preventive Medicine, Multi Organ Failure
Phase 2TerminatedFaron Pharmaceuticals Ltd402017-02-182021-01-14
Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis
BCD-033 (interferon beta 1a), Rebif (interferon beta 1a), Placebo - Multiple Sclerosis
Phase 2 / Phase 3CompletedBiocad1632015-02-122023-02-17
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
BIIB033, Placebo, Avonex - Multiple Sclerosis
Phase 2CompletedBiogen4192013-08-012017-05-03
Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a
IFN beta 1a 44 mcg TIW, Curcumin, Placebo - Multiple Sclerosis
Phase 2CompletedMerck KGaA, Darmstadt, Germany802012-04-302019-01-22
Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide
teriflunomide, Interferon-β-1, Influenza vaccine - Multiple Sclerosis
Phase 2CompletedSanofi1282011-09-012016-02-18
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
VigantOL oil plus interferon beta-1a (Rebif), Placebo plus interferon beta-1a (Rebif), Interferon beta-1a (Rebif®) alone - Relapsing-Remitting Multiple Sclerosis
Phase 2CompletedMerck KGaA, Darmstadt, Germany2602011-02-012016-11-28
Comparing Efficacy and Safety of Inhaled SNG001 to Placebo
Interferon beta 1a, Placebo - Asthma
Phase 2CompletedSynairgen Research Ltd.3002010-03-012012-02-13
Treatment Interruption of Natalizumab
natalizumab, interferon beta 1-a, methylprednisolone - Relapsing Remitting Multiple Sclerosis
Phase 2CompletedBiogen1752010-03-012013-09-19
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
Cholecalciferol (Vitamin D3), Placebo, Rebif - Multiple Sclerosis
Phase 2CompletedMerck KGaA, Darmstadt, Germany1292009-11-012017-12-14
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Placebo, Ocrelizumab, Avonex - Multiple Sclerosis, Relapsing-Remitting
Phase 2CompletedGenentech, Inc.2202008-07-172024-12-31
A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis
BG9418 (Interferon beta-1a), Placebo - Active Ulcerative Colitis
Phase 2CompletedBiogen1232008-05-012014-08-13

Showing 20 of 34. Sign in to see all of them.

Conditions studied

Multiple Sclerosis (15)  ·  Multiple Sclerosis, Relapsing-Remitting (8)  ·  COVID-19 (2)  ·  Colitis, Ulcerative (2)  ·  Recurrence (2)  ·  Alzheimer Disease (1)  ·  Asthma (1)  ·  Burkitt Lymphoma (1)  ·  Crohn Disease (1)  ·  Dementia (1)  ·  Disease Progression (1)  ·  Encephalitis (1)  ·  Inflammation (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Mantle-Cell (1)

Sponsors

Biogen (6)  ·  Merck KGaA, Darmstadt, Germany (4)  ·  Sanofi (3)  ·  Biocad (2)  ·  EMD Serono (2)  ·  Shahid Beheshti University of Medical Sciences (2)  ·  Synairgen Research Ltd. (2)  ·  EMD Serono Research & Development Institute, Inc. (1)  ·  Faron Pharmaceuticals Ltd (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Genentech, Inc. (1)  ·  Genzyme, a Sanofi Company (1)  ·  German Society for Pediatric Oncology and Hematology GPOH gGmbH (1)  ·  German University in Cairo (1)  ·  Multiple Sclerosis Institute (1)

Countries

United States (14)  ·  Italy (10)  ·  Germany (9)  ·  United Kingdom (9)  ·  Russia (8)  ·  Canada (7)  ·  Spain (6)  ·  Switzerland (4)  ·  Austria (3)  ·  Czechia (3)  ·  France (3)  ·  Netherlands (3)  ·  Poland (3)  ·  Denmark (2)  ·  Estonia (2)

Top investigators

Claudia Pena Rossi, M.D. (2)  ·  Allan Ropper, MD (1)  ·  Andrea Paolillo, MD, PhD (1)  ·  Behnam Rahimi, M.D (1)  ·  Carlo Pozzilli, MD (1)  ·  Emmanuelle Waubant, MD PhD (1)  ·  Emmanuelle Waubant, MD, PhD (1)  ·  Fabiana Marinelli, MD (1)  ·  Firouze Hatami, M.D (1)  ·  Fred Lublin, MD, PhD (1)

Results publications

PMID 22622860, PMID 15714427, PMID 18946064, PMID 19145731, PMID 19302707, PMID 20659956, PMID 21397567, PMID 21960587, PMID 22047971, PMID 22442431, PMID 23459567, PMID 23851964, PMID 24170099, PMID 24937476, PMID 25929276, PMID 26049148, PMID 26396053, PMID 27000249, PMID 27995531, PMID 28148632, PMID 28607708, PMID 30027104, PMID 30144037, PMID 31285147, PMID 31454777, PMID 31594857, PMID 32447743, PMID 32493468, PMID 33106183, PMID 33763778, PMID 33850184, PMID 34224994, PMID 34583214, PMID 34882037, PMID 35115574, PMID 36780676, PMID 37272540, PMID 38070031, PMID 38648580

NIH funding

2009 (1), 2014 (1), 2017 (1), 2019 (1)